With the market heading into 2026, investors are looking for companies that can keep delivering strong revenue and expanding margins, along with ...

Insulet delivers strong fundamentals, with robust revenue growth, high margins, and impressive returns on capital, driven by Omnipod's success. PODD's Q3 results were strong, featuring record revenues ...

Fintel reports that on November 19, 2025, UBS upgraded their outlook for Insulet (NasdaqGS:PODD) from Neutral to Buy. Analyst Price Forecast Suggests 9.42% Upside As of November 17, 2025, the average ...

(Photo by Kirk Mckoy/Los Angeles Times via Getty Images) When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: ...

BOC Sciences is teaming up with innovators at the PODD Conference 2025 to fast-track the next generation of drug delivery. The future of medicine rests, in large part, on effective delivery systems.

The annual Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics. The 15th annual Partnership Opportunities in Drug Delivery (PODD) ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy of ...

Insulet PODD shares soared 7.2% in the last trading session to close at $264.72. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with ...

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors? We ...